BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy

Font, Albert; Tarón, Miquel; Costa, C.; Layos, Laura; Pérez-Roca, Laia; Sánchez, Javier Sánchez; Chaib, Imane; Mora, M; Gago, J.; Rosell, R.

doi:10.1200/jco.2008.26.15_suppl.5021

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, BRCA1 mRNA expression levels predicted outcome following cisplatin-containing chemotherapy in non-small-cell lung cancer [18]. Along the same lines, in a retrospective study of locally advanced bladder cancer patients treated with cisplatin-based chemotherapy, those with low or intermediate levels of BRCA1 mRNA attained significantly better response, disease-free survival and OS than those with high levels[36].…”

Section: Discussionmentioning

confidence: 96%

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

et al. 2010

View full text Add to dashboard Cite

BackgroundA fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA.Methodology/Principal FindingsTumor biopsies were obtained from 86 breast cancer patients who were candidates for neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray. HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with significantly longer survival.Conclusions/SignificanceWe provide evidence for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings can be useful for customizing chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 96%

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Among those genes, topoisomerase IIa (target of doxorubicin) was down-regulated in the nonresponder group. Correlation was found between low/intermediate BRCA1 mRNA levels (which mediates DNA repair) and pCR as well as long-term outcomes with neoadjuvant cisplatin-combination chemotherapy for bladder cancer in a retrospective study of 49 patients [27]. In the setting of neoadjuvant therapy of breast cancer, early modulation of pharmacodynamic biomarkers (e.g.…”

Section: Discussionmentioning

confidence: 99%

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

Sonpavde

Goldman

Speights

et al. 2009

Cancer

181

101

View full text Add to dashboard Cite

“…As far as (ii) is concerned, although G-CSF-supported HD-MVAC might be a reasonable chemotherapeutic choice for younger 'fit' patients, there is no definite trial to support this regimen. In addition to (vi), excision repair crosscomplementing 1 (ERCC1) and breast cancer 1, early onset (BRCA1) mRNA expression have been shown as predictive of poor response to cisplatin-based chemotherapy; the latter in the neo-adjuvant setting [115,116] .…”

Section: Expert Opinion and Conclusionmentioning

confidence: 99%

Novel therapeutics in metastatic bladder cancer

Lekas

Papathomas

Papatsoris

et al. 2008

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background : Albeit transitional cell carcinoma of the urinary bladder is a chemosensitive neoplasm, metastatic disease is related with poor prognosis and short-term survival data. Objective : Cisplatin-based combination chemotherapy is recognised as the golden standard therapy for patients with inoperable locally advanced or metastatic bladder cancer. However, owing to treatmentrelated toxicities and short-response durations, novel treatment options or agents, with both enhanced efficacy and tolerability, have been sought.Methods : Reviewing the current status and addressing the future of novel anticancer therapeutics in metastatic urinary bladder cancer. Results/conclusion : Non-platinum, single agents, such as gemcitabine and taxanes, as well as multidrug regimens in doublet or triplet chemotherapeutic combinations are regarded as promising alternatives. Dose intensification of conventional regimens, dose-dense sequential administration of new agents, the use of molecular markers for predicting chemosensitivity and the integration of biologically targeted agents to enhance chemotherapeutic efficacy are promising approaches.

show abstract

BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy

Cited by 10 publications

References 0 publications

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

Novel therapeutics in metastatic bladder cancer

Contact Info

Product

Resources

About